🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/10/2020 227,80 231,20 227,00 230,40 +0,70% 1,84% 45.737
05/10/2020 230,20 231,80 225,60 228,80 +0,53% 2,69% 97.579
02/10/2020 226,20 229,40 224,60 227,60 -0,18% 2,12% 89.423
01/10/2020 225,60 229,20 223,80 228,00 +1,33% 2,39% 71.056
30/09/2020 221,00 228,00 221,00 225,00 +1,17% 3,17% 90.341
29/09/2020 218,20 222,40 215,20 222,40 +2,21% 3,30% 57.870
28/09/2020 213,00 218,40 211,60 217,60 +3,82% 3,19% 79.865
25/09/2020 209,20 209,60 204,60 209,60 +0,00% 2,39% 55.172
24/09/2020 209,80 212,60 206,00 209,60 -0,29% 3,15% 104.943
23/09/2020 208,00 210,60 204,80 210,20 +1,74% 2,79% 94.737
22/09/2020 210,00 211,80 202,80 206,60 +0,49% 4,29% 115.747
21/09/2020 208,20 209,60 203,80 205,60 -0,48% 2,79% 85.660
18/09/2020 205,00 209,40 203,00 206,60 +1,47% 3,12% 346.131
17/09/2020 200,00 204,80 200,00 203,60 +2,06% 2,40% 85.239
16/09/2020 199,10 200,40 197,30 199,50 +0,35% 1,56% 61.896
15/09/2020 195,00 200,60 194,60 198,80 +2,47% 3,08% 106.723
14/09/2020 189,30 194,20 187,60 194,00 +2,54% 3,49% 128.363
11/09/2020 185,40 189,70 184,00 189,20 +0,96% 3,07% 86.500
10/09/2020 193,80 193,80 185,10 187,40 -3,00% 4,49% 83.288
09/09/2020 187,80 193,70 187,80 193,20 +2,77% 3,14% 86.434
08/09/2020 191,90 191,90 182,80 188,00 -1,47% 4,74% 172.986
07/09/2020 183,40 192,20 183,40 190,80 +4,15% 4,80% 106.420
04/09/2020 182,70 188,50 180,10 183,20 -0,81% 4,60% 137.950
03/09/2020 191,00 192,30 183,70 184,70 -2,48% 4,50% 120.931
02/09/2020 191,80 194,70 188,20 189,40 -0,26% 3,39% 172.206
01/09/2020 196,40 200,40 188,50 189,90 -1,96% 6,06% 137.876
31/08/2020 194,90 201,00 192,00 193,70 -0,67% 4,62% 2.368.618
28/08/2020 194,70 195,40 191,70 195,00 -0,76% 1,90% 153.834
27/08/2020 198,00 199,50 194,20 196,50 -2,14% 2,68% 123.504
26/08/2020 202,00 202,00 198,70 200,80 +0,40% 1,63% 101.019